CADILA HEALTHCARE , Lipaglyn Launched in India - Survey suggests quick market acceptance, if priced appropriately
![](/report_cover/5562/cadila-healthcare-lipaglyn-launched-in-india_en.gif)
Zydus today announced the launch of its novel dual PPAR agonist Lipaglyn (saroglitazar) for treatment of diabetic dyslipidemia patients not controlled by statin alone. Based on our physician survey / assessment of the drug profile / market analysis, we expect Lipaglyn to garner around INR 650 million in peak sales in India by 2016. We see the need of a fixed dose combination of Lipaglyn with statin as important for the quick ramp up for this novel compound.